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resumo 
 
 
Ensaios clínicos de Biodisponibilidade/Bioequivalência são uma área 
promissora em I&D Farmacêutico, e é muito interessante estar envolvida neste 
âmbito. Durante o estágio pratiquei atividades de assistência a ensaios clínicos 
de Biodisponibilidade/Bioequivalência sendo este o meu alvo de intervenção na 
Blueclinical durante dez meses. Durante este tempo também tive oportunidade 
de exercer atividades de enfermagem de investigação devido à minha formação 
anterior na área. 
 
Este relatório tem como objetivo descrever as atividades em que estive 
envolvida, os pontos de aprendizagem e a experiência adquirida em relação à 
condução de ensaios clínicos de Biodisponibilidade/Bioequivalência. 
 
Durante o estágio desenvolvi atividades de assistência de ensaios clínicos e 
aprendi muito sobre o processo de condução do ensaio, desde a submissão do 
ensaio junto das autoridades para obter a sua autorização até ao processo de 
relatar os resultados. 
 
Este trabalho foi um desafio e um processo de aprendizagem contínua. No final 
desta etapa, sinto que foi um esforço recompensado e desejo continuar a 
desenvolver as minhas capacidades nesta área. 
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abstract 
 
 
Bioavailability/Bioequivalence clinical trials are a promising area in 
Pharmaceutical R&D and it is very interesting being involved in this field. During 
the internship, I practiced assistance activities to Bioavailability/Bioequivalence 
clinical trials and this was my target for intervention within Blueclinical during ten 
months. During this time I also had opportunity to exercise nursing research 
activities due to my previous training in the area. 
 
This report aims to describe the activities in which I was involved, the learning 
points and the experience achieved about the conduction of 
Bioavailability/Bioequivalence clinical trials. 
 
During the internship I have developed clinical trial assistance activities and I 
learned a lot about the process of trial conduction, from the submission to the 
authorities to get their approvals until the process of reporting the results  
 
This job was a challenge and a continuous learning process. At the end of this 
period, I feel it was a rewarded effort and I would like to keep developing my skills 
in this area. 
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 Introduction  
 
This report aims to describe my curricular training in order to complete the Training Programme in 
Pharmaceutical Medicine and obtain a Master Degree in Pharmaceutical Medicine. 
I have been in Blueclinical Phase I Unit as a Clinical Trial Assistant (CTA) trainee for ten months, 
since 3rd September, 2013.  During this time, I also had the opportunity to perform some nursing 
activities related with Phase I Clinical Research because of my background of Licensed and 
Registered Nurse.  
Globally, I would like to expand my knowledge in clinical research, but more specifically on Phase I 
clinical trials activities. Also, if needed, combine two roles, CTA and Research Nurse, alternating 
between one and another, but essentially I aim to gain experience in clinical trial assistance.  
At the next point I will identify the objectives I proposed myself to reach during the internship, 
dividing it, in two sections: as CTA and as Research Nurse, but as I said before I will give more 
relevance to the CTA role. 
1.1. Training objectives 
 
As a Clinical Trial Assistant,  
 Acquire competencies to contribute to the review of protocols and other study related 
documents; 
 Develop my communication skills, communicating with sponsors and study teams; 
 Improve my knowledge and capacity to apply International Conference of Harmonization - 
Good Clinical Practice (ICH-GCP) and Helsinki Declaration on my daily work conduct;  
 Learn that clinical trial procedures are performed in compliance with study protocols, 
national policies and standard procedures, GCP and applicable regulatory requirements in 
the Unit; 
 Know better and apply legislation (either national or international legislation, European and 
ICH-GCP guidelines for the management of clinical trials and mechanisms for licensing of 
products) applicable to clinical research activity;  
 Learn how to create strategies to organize the agenda and efficiently be compliant with the 
defined deadlines; 
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 Provide assistance to clinical staff by organizing files, projects, data, etc. and be responsible 
for general office management to keep operations running smoothly; 
 Understand how to assist the development and execution of clinical trials; 
 Assist with routine data verification and quality control, ensuring data integrity and 
consistency with prescribed study protocol; 
 Improve my performance of literature searches, research, and overall administrative 
assistance; 
 Learn how to ensure worksheets are correctly completed by staff and pre-dose activities 
are finalized on time before dosing occasions; 
 Continuously assess and suggest improvements for clinical operations processes to ensure 
safety of study participants and delivery of high quality data; 
 Contribute to data entry and Case Report Form (CRF) completion; 
 Participate in the development, review and revision of Blueclinical SOPs and policies; 
 Contribute to risk assessment and management and support the Quality Manager. 
As a Research Nurse, 
 Carry out clinical study procedures during screening, dosing and discharge, ensuring and 
monitoring safety and wellbeing of study participants (healthy volunteers); 
 Carry out clinical activities in the Unit and screening area such as venepuncture, ECGs, vital 
signals monitoring, and other protocol specific assessments; 
For both of these functions, at the end of this period, I would like to perform the different tasks 
autonomously, be able to maintain the unit calm and organized, and regularly perform self-
evaluation and try to improve my professional performance in order to contribute to high quality 
clinical research.  
This report is structured in 6 chapters. Chapter 1 presents the introduction where are listed my 
personal training objectives. Chapter 2 includes an overview of the host institution – Blueclinical. 
The state-of-the-art is placed in Chapter 3. Chapter 4 describes the tasks I performed during the 
training. The tasks are divided in two main sections, multidisciplinary and monodisciplinary training. 
The last two chapters, 5 and 6, relates the discussion and conclusion, respectively.  
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 Overview of the host institution – Blueclinical 
 
Blueclinical operates in three different areas: Blueclinical Phase I; Blueclinical Clinical Research 
Partnership (CRP) and Blueclinical R&D. 
Observing the Blueclinical organogram, (Appendix A) illustrates the relations between people 
within the different departments. It also enables to visualize the complete Blueclinical structure 
and organization. 
 
2.1. Blueclinical Phase I 
 
Blueclinical Phase I was inaugurated at July 12, 2013 and it aims to conduct of Phase I studies in 
healthy subjects and early proof-of-concept studies in selected patient populations. This is the area 
where I was allocated to conduct my role as CTA. 
Phase I studies in healthy subjects are performed in an exclusive and dedicated 29-bed unit located 
at Hospital da Prelada, Level 3, Oporto, Portugal, with appropriate facilities to the clinical trials 
conduction. The team has physicians, nurses, pharmacist, clinical trials assistants, laboratory 
technicians and project managers working on planning and conduction of Phase I clinical trials (1). 
 
2.2. Clinical Research Partnership  
 
Clinical Research Partnership (CRP) supports and collaborates with clinical research centers, 
promoting their growth, efficiency gain in clinical research sponsored by the pharmaceutical and 
medical devices industry or investigator-driven (1). 
CRP is a growing network of hospitals and primary care centers that serve a significant percentage 
of the Portuguese population. The full network operates under a common quality management 
system to create value in clinical research. 
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2.3. R&D Consultancy 
 
Blueclinical R&D aims to provide expert advice on clinical research opportunities resulting from 
“translational medicine”. It can also prepare and implement all the phases of development plans of 
news drugs, medical devices and other health products. 
There are other activities, such as: preparation and monitoring of scientific and regulatory advice; 
planning and supervision of pharmaceutical development and analytical methods; preparation of 
the investigator’s brochure and the investigational medicinal product dossier (IMPD); portfolio 
selection support and analysis and support in the preparation of the business plan and application 
for funding (1). 
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 State-of-the-Art – Pharmaceutical R&D and BABE clinical trials 
 
During the training I was dedicated to learn, mostly, about BABE clinical trials conduction, for this  
reason, this chapter is dedicated to this topic. 
 
3.1. Pharmaceutical R&D overview  
 
Science and technology advances are leading to new research methods and promising expectations 
for the future. Pharmaceutical R&D also contributed to a life expectancy increase, up to 30 years 
longer than a century ago to European Union (EU) citizens (2). 
Over this time, the process of R&D and the industry have changed their strategies from the 
blockbusters1 (3) approach to a more specific and specialized approach where the clinical trials are 
more rigorous and cost-effective designed(4). To reach these goals, some of the strategies taken 
were related with regulatory aspects, which directly influenced the companies’ 
organization/structure, processes and strategies, so it is crucial and challenging to a company to be 
compliant with these requirements and follow the most updated guidelines (5, 6). 
EU and United States of America (USA) legal framework for medicinal products for human use can 
differ in some aspects, for example, USA is quicker regarding the regulatory aspects (7), but both 
agencies aim to ensure a high level of public health protection and to encourage innovation, and 
are responsible to concede the marketing authorization (8). 
Despite the changes that were implemented, the Pharmaceutical R&D is still a long (almost 4 years, 
see Figure 1), expensive (see Figure 2) and complex process. To reach the success, most of the 
times, there were plenty of failures before (9). 
                                                          
1 Blockbusters drugs are generally defined as drugs that solve medical problems common to hundreds of 
millions of people and, at the same time generate large sales increases and profits for the pharmaceutical 
companies. 
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Figure 1 – New drug development time (months) comparing a traditional and an adaptive approach. Available from: The 
World Economic Forum, 2013 (9). 
 
 
Figure 2 – New drug development costs (millions US$) per phase. Available from: The World Economic Forum, 2013 (9). 
US and EU, perform most of the clinical trials, although with the recent international harmonization 
of procedures and the standardization of the requirements, some countries, called emerging 
regions, such as Eastern European, Latin American and Asian countries are now increasingly 
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receiving industry-sponsored clinical research as it is presented in Figure 3. This opposes the trend 
of the traditional places such as North America, Western Europe and Oceania. Now, developing 
countries are more attractive because of their lower cost per patient which leads to increased 
economic profits (9). 
 
Figure 3 – Trial density is indicated by color, with the darker color having higher densities. Annual growth rate is indicated 
for some countries. Available from: Thiers FA, Sinskey AJ, Berndt ER, 2008 (10). 
It is also interesting to look at the numbers for positive opinions released by the European Agency 
of Medicines (EMA) concerning medicines for human use, Figure 4, shows an increase from 57 
positive opinions in 2012 to 81 positive opinions in the past year. In accordance with Regulation 
(EC) No 726/2004, the Committee for Medicinal Products for Human Use (CHMP) is the responsible 
body inside the Agency to answer the questions concerning medicines for human use (11).  
 
Figure 4 – CHMP opinions for medicines for human use, since 2009 until 2013. Adapted from: European Medicines Agency 
– EMA, 2013 (12). 
The challenge is to understand the need of new treatments or the need of improving the existing 
ones, expanding the scientific knowledge and its complexity, and be competitive with the 
developing markets (13). 
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3.2.  Phase I to IV and Bioavailability and Bioequivalence Clinical Trials Worldwide  
 
Clinical trials and the process of clinical development of pharmaceuticals for human use can be 
divided in four temporal phases (I-IV) (14): 
Phase I  
This phase respects to the first administration of a new drug into humans. At this phase of 
development, a small group of people is involved, usually 20 to 80 participants, these participants 
are usually healthy volunteers. The objective is to evaluate safety, determine a safe dosage range, 
and identify side effects (14). 
Phase II 
“Phase II is usually considered to start with the initiation of studies in which the primary objective is 
to explore therapeutic efficacy in patients.” in General Considerations for Clinical Trials, ICH-E8 (14). 
The number of participants is usually 100 to 300 (15). 
Phase III  
“Studies in Phase III are designed to confirm the preliminary evidence accumulated in Phase II that 
a drug is safe and effective for use in the intended indication and recipient population.” in General 
Considerations for Clinical Trials, ICH-E8 (14). 
Involves a large population in study, the number of participants can reach to thousands (1000-3000) 
(15). 
Phase IV – Post -Marketing 
It involves the safety surveillance (pharmacovigilance) starting after drug approval. This type of trial 
aims to provide additional information on longer-term safety and side effects and also are useful 
for optimize the drug’s use or to test the product in different populations of people, such as children 
(14, 15). 
 
Bioavailability and Bioequivalence (BA/BE) 
During the internship I participated in several BA/BE clinical trials, and therefore, the report will 
focus on this subject. 
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BA/BE  clinical trials are a growing market due the patent expiring in the next years (10, 16).  
BA/BE trials were first established in 1984 by The Drug Price Competition and Patent Term 
Restoration Act, informally known as the "Hatch-Waxman Act" [Public Law 98-417], this is a federal 
law in United States which encouraged the manufacture of generic drugs by the pharmaceutical 
industry and established the modern system for government generic drug regulation (17). 
Bioavailability is defined in Code of Federal Regulations (CFR) 320.1 as:  
“The rate and extent to which the active ingredient or active moiety is absorbed from a drug product 
and becomes available at the site of action. For drug products that are not intended to be absorbed 
into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate 
and extent to which the active ingredient or active moiety becomes available at the site of 
action.”(18). 
Bioequivalence is defined in CFR 320.1 as:  
“The absence of a significant difference in the rate and extent to which the active ingredient or 
active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at 
the site of drug action when administered at the same molar dose under similar conditions in an 
appropriately designed study.”(18). 
To get approval for generic medicines the most important parameters evaluated are: 1) 
bioequivalence (defined above); 2) maximum drug concentration (Cmax) is the parameter used to 
characterize the absorption rate and 3) the area under the plasma drug concentration-time curve 
(AUC) is the parameter used to characterize the extent of drug absorption. Comparing the test and 
the reference drugs, Cmax and AUC are restricted to vary within a certain limited range to be 
approved as a generic version (19).  
In terms of numbers, Figure 5 shows that the healthy, diabetes and fasting/ fed conditions are the 
most commonly researched conditions among bioequivalence and bioavailability studies registered 
in ClinicalTrials.gov (20). 
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Figure 5 – Most commonly researched conditions Adapted from: Spigarelli MG, Stockmann C, 2013 (20). 
As mentioned above, the migration of the industry-sponsored clinical research to emerging 
countries seriously affected BA/BE clinical trials market, constituting a huge competition in the 
marketplace with very competitive prices compared to those prevailing in developed countries (9). 
The global distribution of ongoing bioequivalence and bioavailability trials is shown in Figure 6. 
This figure shows that the majority of the BA/BE trials are being conducted in North America, 
however East Asia, Middle East and South America also have ongoing bioequivalence and 
bioavailability trials (20). 
 
Figure 6 – Ongoing Bioequivalence and Bioavailability Trials Registered in ClinicalTrials.gov between 01 October 2007 and 
31 December 2012. Adapted from: Spigarelli MG, Stockmann C, 2013 (20). 
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The pharmaceutical industry will continue to face changes and challenges, regarding global 
economic uncertainties and the increasing spending on pharmaceuticals. These changes will modify 
the global pharmaceutical prospect, which must increase productivities and improve efficiency (20). 
The spending on pharmaceuticals over the next years tends to continue to increase, because of the 
growing use of medication and population, as global population raises. The next years will have a 
big number of patents expiring, leading to an increase of the generics market (16). 
 
3.3. Phase I Clinical Trials in Portugal 
 
The number of undergoing clinical trials in Portugal between 2006 and 2013 fell 28.75%, from 160 
to 114 studies (see Figure 7). The lowest number of clinical trials submitted in Portugal since 2006, 
was reached in 2011, with only 88 studies (21). 
 
Figure 7 – Submitted cases for authorization (2006-2013) – adapted from INFARMED website (22). 
During 2013, ten (10) Phase I clinical trials have been submitted and validated by INFARMED (22), 
and Blueclinical was responsible for five of them, these were clinical trial applications of BA/BE 
clinical trials. 
 shows the number of Phase 1 clinical trials submitted and validated since 2005 until last year. 
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Table 1 – Number of Phase I Clinical Trials submitted and approved since 2005 Available from: INFARMED website (22). 
2005 (2nd sem) 2006 2007 2008 2009 2010 2011 2012 2013 
3 2 7 3 6 2 6 3 10 
 
In this moment of economic crisis that Portugal is going through, and to rationalize the use of drugs 
in financial terms, generic drugs emerge as an opportunity due to its lower cost. In Portugal, the 
proportion of generics has increased steadily, approaching in August 2013, 40% of medicines 
reimbursed by National Health System (NHS) and this percentage is intended to be expanded to 
60% in 2014 (23). Regarding this, Portugal would benefit from better use of national capacities for 
clinical research, specially this growing generic market, but to achieve this, we need to improve 
some aspects related to planning and project management, and reduce the administrative 
complexity (24, 25). 
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 On-the-Job Training 
 
4.1.  Multidisciplinary training  
 
In this section I will describe the generic skills to better play my role, for example, the understanding 
of the main regulations and legislation applicable to clinical research, the Helsinki Declaration and 
the reading and understanding of Standard Operating Procedures related to Blueclinical activities. 
 
 Regulations and legislation 
 
The pharmaceutical industry is highly regulated and Phase I clinical trials are not an exception. Drug 
development has been suffering changes to improve the process, these changes include, mainly 
regulatory aspects and the increase of transparency in the drug development. 
With the overall aim of harmonizing the procedures for conducting clinical trials with regard to 
regulatory, scientific and ethical aspects throughout Europe results the Directive 2001/20/EC in 
2004, which was transposed into national law of each Member State. 
Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 defines the 
requirements for the conduction of clinical trials in the EU “on the approximation of the laws, 
regulations and administrative provisions of the Member States”(26). 
However, almost a decade after its implementation several opportunities were found for 
improvements of the current Directive, for example, the transposition for each Member State 
verifies some discrepancies, increased bureaucracy and hence increased costs. 
For these reasons, in July 2012 the European Commission suggested and implemented a proposal 
for a new European Regulation to replace the current Directive (27). 
The Good Clinical Practices (GCP) Directive 2005/28/EC April 8, 2005 results from the Directive 
2001/20/EC. 
In Portugal Directive 2001/20/EC resulted in Law 46/2004 of 19 August which has recently been 
replaced by Law 21/2014 of 16 April. GCP Directive 2005/28/EC resulted in Decree-Law 102/2007. 
Beyond these should always be applied the Law 67/98 of 26 October, on the protection of personal 
data. 
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Internationally and according the ICH-GCP, the regulation of all these aspects are harmonized and 
ensures integration, in a regulatory basis of the principles, guidelines and quality requirements that 
should govern the conduct of these studies, in order to protect all subjects who participate. These 
were the main objectives of the extensive legislation that has been recently produced and which is 
compiled in volume 10 of EudraLex (28).  
BA/BE trials to non-EU countries, must comply with the regulations of the different regulatory 
agencies.  
 
 Helsinki Declaration  
 
Nowadays, the ethics applied to research, both to social sciences and biomedical research, 
unfortunately were built on mistreating human beings and disrespecting ethical values. Nuremberg 
Code is an example of this, it was created in August 1947, in Nuremberg, Germany, by American 
judges sitting in judgment of Nazi doctors accused of conducting murderous and torturous human 
experiments in the concentration camps (29, 30). 
The Declaration of Helsinki is one of the major ethical guidelines for conducting clinical research. 
Along its existence it has been modified in several different occasions and the last version was 
released in October 2013. The Declaration is an important document in the history of research 
ethics, and stands as the first major effort of the medical community to regulate research itself. It 
is considered to be the 1st international standard for biomedical research and is the basis of most 
subsequent documents (31). 
The Declaration of Helsinki has nearly half-century of existence and it defines the Ethical Principles 
for Medical Research involving Human Subjects, this principles are developed by a medical 
community - World Medical Association (WMA). The Declaration includes principles on 
safeguarding research subjects, using correctly the informed consent, minimizing the risks and 
adhering to an approved research plan/protocol. Declaration of Helsinki and the EU Clinical Trials 
Directive (2001/20/EC) are fundamental to research governance of clinical trials. Both are 
applicable to non-commercial (research council, charity-funded) trials and commercial trials (those 
funded by pharmaceutical companies) (31). 
The current version  (October 2013) replaces the previous versions (32). The newest version is 
concerned with the growing clinical research in developing countries and its dangers to their 
vulnerable populations. And therefore, strives to increase the liability of the sponsors, the 
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transparency in the disclosure of the results and also that all participants have the opportunity to 
benefit from the innovative treatments after the end of the clinical trial (33). Also, the new version 
of The Helsinki Declaration includes, for the first time, the issue of compensation and treatment for 
participants harmed by participating in research (34). 
 
 Standard Operating Procedures  
 
Standard Operating Procedures (SOPs) can be defined as “Detailed, written instructions to achieve 
uniformity of the performance of a specific function.”(35) A SOP can have one or several support 
documents, also known as SuDocs, and it can be defined as documents used to complete or record 
an action described in the SOP to which it is associated, or as a stand-alone document for a specific 
activity. The SOP’s creation is based in the local law and applicable regulations. All the Blueclinical 
players of a specific procedure should follow the applicable and most updated version. 
One of the first tasks I had when I arrived to Blueclinical was the SOP’s reading to better understand 
the functioning of the unit, and definitely it was a good help, because it provides a wide perspective 
about how things work or should work. 
SOP is not rigid, so after the SOP implementation some aspects can change, and if applicable, the 
SOP can be updated. Quality control is a constant to keep the SOPs updated and according the 
needs and the established practice. The introduced changes can be simple administrative changes 
or critical changes requiring the compliance with a new/updated international or local regulatory 
requirement, or to address an audit or inspection finding. In both cases an intervention is required, 
and all the interveners are requested to be aware of the change, and act according the latest 
version. SOPs are important because it ensures that all research conducted within the Blueclinical 
follows the applicable regulations, ICH GCP, and institutional policies to protect the rights and 
welfare of human study participants. SOPs can also be used as a guide to explain how research will 
be conducted within the Blueclinical and provides an excellent training tool for new employees. 
My intervention in this area was related with some updates. Some were related to clinical 
procedures and others to clinical trial operations and some new SOP’s creation of clinical 
procedures, then submitted to revision and approval. I was more active regarding to SOPs related 
to clinical procedures due my background, but I also had the opportunity to collaborate in some 
updates of SOPs related with clinical trial operations and activities.  
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4.2.  Monodisciplinary training 
 
In this section I will illustrate the specific tasks that I performed along the training. I will describe 
mainly my experience as Clinical Trial Assistant, that was my principal intervention, but also a few 
tasks performed as Research Nurse. 
 
 My experience as Clinical Trial Assistant 
 
Since the training started I have already actively participate in several BA/BE clinical trials, the 
activities I could perform are described below. 
4.2.1.1. Clinical Trial Activities 
 
4.2.1.1.1. Clinical Trial Applications 
 
In accordance with the Directive 2001/20/EC, before submitting an application to the Competent 
Authorities (CA), it must be obtained a unique EudraCT (European Union Drug Regulating 
Authorities Clinical Trials) number from the EudraCT database. In order to obtain the EudraCT 
number automatically the database needs some few information, such as, requestor's organisation 
name, town/city and country; Sponsor's protocol code number; requestor name; e-mail to which 
the EudraCT number will be sent; security code; whether the clinical trial is contained in a Paediatric 
Investigation Plan (PIP); whether the clinical trial will be conducted in a third country (outside of 
the EU/EEA); and the Member States where it is anticipated that the trial will be run. During the 
training I had the opportunity to participate and understand how this process works and how the 
number is obtained, I found it very easy and quick. 
After the clinical trial has a EudraCT number allocated, a clinical trial application (CTA) must be 
filled,  this is a unique, EU-wide clinical trial application form provided for and published in Volume 
10 of EudraLex — The Rules Governing Medicinal Products in the EU. CTA is filled carefully to avoid 
mistakes and reviewed by at least a second person, performing Quality Control. In Portugal the 
form is submitted in paper, so the full clinical trial application form is saved as an XML file and 
submitted on a CD-ROM with several other submission documents. 
The submission consists of a valid request for authorization to the competent authority of the 
Member State in which the sponsor plans to conduct the clinical trial. In Portugal, the competent 
authorities that must authorize the clinical trial are: National Competent Authority - INFARMED, 
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Ethics Committee - CEIC and National Commission for Data Protection, Comissão Nacional de 
Proteção de Dados - CNPD. 
The procedure is quite identical with regard to both the (INFARMED) and the (CEIC)(36). Both these 
authorities provide the structure of the contents that an application must contain to be validated, 
which includes a large organization of documents related to the trial. This structure is available on 
INFARMED and CEIC webpages. 
Regarding the confidentiality and data collection during the trial, the data protection authority 
CNPD must also give their authorization. CNPD submission it is usually done first because they 
request less information than INFARMED and CEIC, and the submission follows an electronic 
format. 
After the submission, the process must then be validated, and after the expert evaluation and a 
plenary meeting, and according the meeting agreements, an authorization can be issued. During 
this process, the authorities are able to raise questions that should be answer as soon as possible 
in order to do not delay the procedure of authorization. In case of substantial changes 
(amendments), the authorities must be informed, during all the time of the lifetime of the trial 
(submission until LPLV). In case of a non-substantial amendment the sponsor do not need to notify 
the CA, but the information should be available in the trial documentation. (see Figure 8) 
To define an amendment as substantial or not (37), depends if the amendment is likely to have a 
significant impact on: 
 the safety or physical or mental integrity of the subjects; 
 the scientific value of the trial. 
I followed several submissions to the competent authorities and I could understand the granularity 
of the submission documents and the specific requests from the different authorities. It is a process 
that requests good organizational and management skills, because the in charge person must 
collect all the necessary documents and organize them according the provided structure from the 
authorities. So, being able to participate in this task allowed me to improve the organizational 
competency and at the same time, I learned, in detail, the steps of the clinical trial application to a 
national level.
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Figure 8 – Competent Authorities Submission Process - Portugal
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4.2.1.1.1. Trial Master File (TMF) 
 
TMF is a document that goes along the clinical trial and retains relevant information related with 
the trial. It works as a standard, central and orderly filing system which allows the effective storage 
and location of the large volume of regulatory and approvals documents needed for clinical 
research (38). 
The European Directive 2005/28/EC describes the TMF as “essential documents, which enable both 
the conduct of a clinical trial and the quality of the data produced to be evaluated”.  
These essential documents are defined by ICH GCP, Section 8.1 as those that individually and 
collectively permit evaluation of the conduct of a trial and the quality of the data produced. 
I contributed to the TMF construction during the trials I had participated. I learned that the TMF 
must be updated on an ongoing basis to ensure it is always audit and/or inspection ready.  
As a CTA I had the opportunity to: 
 Document management and archiving; 
 TMF maintenance until the study is formally closed and allow direct access to all 
requested essential documents by the monitor, auditor, Ethics Committee or 
regulatory authorities; 
 Verify there are no missing documents; 
 Ensure that required essential documents are on file.  
TMF should be organized according the applicable directives and guidance aiming to assist with the 
trial management, GCP compliance and possible inspections. The sites that are responsible for the 
conduction of the trial must kept a TMF but the Sponsor should also organize their own TMF or 
might delegate this task to the site. 
During the trials conducted in Blueclinical Phase I facilities, I had the opportunity to organize the 
site TMF in parallel with the Sponsor TMF. Reviewing and confirming that all necessary documents 
were available for close-out visits and inspections allowed me to get more aware of the essential 
documents needed. (39). 
Blueclinical Phase I has a specific SOP to standardize the table of contents defining the TMF 
structure, so, at each trial the defined structure is used. The contents’ structure was created 
according the Directive 2001/20/EC. 
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During this process, I had the opportunity to organize and review several TMF’s, and it made me 
understand its importance. I learned how it is the crucial to future enquiries to the trial. On the 
other hand I feel that this process could be transformed in an electronic storage that is safer and 
more eco-friendly. 
 
4.2.1.1.2. Recruitment 
 
Potential trial volunteers are recruited from an electronic database of people who have indicated 
their willingness to participate in a trial. 
The main dissemination strategy for the recruitment of healthy volunteers is the announcement on 
Blueclinical website where it is provided general information about Phase I clinical trials and its 
procedures. The potential volunteers can sign up by filling out a form with some personal details 
(approved by CEIC and CNPD). 
Blueclinical methods and strategies used for recruiting healthy volunteers for Phase I clinical trials 
are defined by the Clinical Research Manager (CRM), as needed. The process ensures specific 
recruitment of healthy volunteers for clinical trial data in accordance with ethical and legal 
requirements and with the approval of the CEIC and the CNPD.  
I had the opportunity to create several memorandums with the trial details and relevant 
information, which helped me substantially in the recruitment procedure. It is a useful tool to use 
when the recruitment is by phone because it is a good guidance. It also helps to communicate 
relevant information and pre-screening the main inclusion/exclusion criteria to the trial. The 
memorandum is based on the protocol and the informed consent form and must be approved by 
Clinical Director (CD) or other person designated by him. 
Recruitment requires a good preparation to answer to a different range of questions related with 
the trial. I spend several hours recruiting volunteers. Each call can only take a few minutes or can 
be much longer than that, it depends on the knowledge of the person that is listening and the 
questions asked. 
I learned that a good strategy of recruitment by phone is: keep it simple! Detailed information is 
given at the screening period when all the written information (Informed Consent) is provided to 
the volunteer. 
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I had the opportunity to perform this task during the trials I participated, it can be a hard task for 
several reasons: 
 The Blueclinical database is still increasing to be able to provide the number of needed 
volunteers to participate in each trials, so every recruitment periods were very difficult to 
reach the numbers of volunteers needed. 
 The recruitment is performed by phone, and each call requests different type of 
communication, the person on the other side of the telephone can question a lot of aspects 
or do not question anything at all, it is variable. It should be maintained an easy vocabulary 
but at the same time everyday words can mislead, so I learned we should be transparent 
but cautious with the vocabulary used to inform volunteers. 
Independently of the recruitment method used, the volunteers must be recruited of their own free 
will. I also had the opportunity of manage the volunteer’s database. After the volunteer participate 
in a clinical trial he must be absent of any clinical trial participation at Blueclinical or other institution 
for at least 3 months, and during one year can only participate in 2 clinical trials. Blueclinical keeps 
a record of volunteers who participate to avoid excessive use of any volunteer.  
These tasks allowed to achieve the following goal I proposed in the beginning of the training: 
“Develop communication skills” through the contact with potential volunteers, recruitment by 
phone, contacting by email and face-to-face. 
 
4.2.1.1.3. Investigator’s Meeting 
 
Before the clinical trial begins and after the Competent Authorities approval the Investigator’s 
Meeting takes place. At this moment all team members that will take part of the clinical trial must 
be present and be authorized by the Principal Investigator (PI) to participate, PI also delegates the 
tasks that will be performed by each member during the trial according to their competencies. 
During the Investigators Meeting it is discussed the protocol specificities, GCP and other relevant 
documents/procedures related to the trial such as improvements needed, confronted with the last 
performances. It is like a discussion forum where are debated possible ways to improve 
performance and crucial points to the trial. 
As a CTA I could prepare the meeting support material, make sure all paperwork was correctly 
signed and dated, including the confidential agreements.  
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The support material includes the investigators’ meeting dossier (hard copy) which contains at 
least: Protocol; Investigator’s Brochure; CRF specimen copy and filling instructions; Clinical trial 
timelines; GCP guideline; Helsinki Declaration and other relevant documents. 
I also should ensure that delegation of study tasks form is accurate and complete at the end of 
investigators´ meeting and that investigators’ meeting related documents are archived in the trial 
master file (TMF). 
 
4.2.1.1.4. Screening, Admission, Confinement and Follow-up 
 
Once the volunteer arrives to Blueclinical receives some guidance about the screening procedures, 
also, it is provided the written information (Informed Consent Form – ICF) of the clinical trial. From 
this moment, at least 30 minutes is given to the volunteer to read all the information. After the 
volunteers finishes reading and accepts to participate in the clinical trial the volunteer can proceed 
to the other screening procedures such as, medical examination, vital signs, ECG, blood and urine 
collection, according to protocol specifications. The investigator should evaluate trial volunteers as 
suitable on the basis of tests. At the end of the screening visit the volunteer keeps one of the two 
ICF’s that he have signed and dated and the other ICF is archived in the TMF. 
According the internal procedure to identify the volunteer, a screening number is assigned in a 
sequential order, through the day and time of arrival, and three name initials. 
During the screening process, a volunteer may not get enrolled into the trial for various causes, for 
example, the volunteer not meet the inclusion criteria or meet the exclusion criteria (ineligibility). 
Screening failures must be documented during the screening process. 
The screening is a very important moment when the volunteer decides to participate or not, at this 
time the volunteer receives all written information (ICF’s) and have the chance to clarify all their 
doubts with the team. It also necessary to verify if all documents are properly filled, for example, 
that the documents are all signed and dated correctly. If necessary, the volunteer can take home 
an ICF to reflect or discuss with others, and, if they like to, return later. 
As a CTA, I am involved in all this process, including: 
 the reception and orientation of the volunteer in the unit; 
 the delivery and explanation of the latest version of the ICF; 
 clarifying doubts; 
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 conduct them to the Physician and Nurse; 
 verify the source documents and ICF's and as well as archiving it on TMF. 
Before the volunteer exits the unit, check that everything is signed properly and that all screening 
procedures were performed as expected.  
Upon review of ICFs, I must consider several aspects, such as, the verification if the ICF is identical 
to the lasted approved version; if all the volunteers who complete the screening signed an ICF; if all 
of the ICF were dated and signed personally by either volunteer or by the investigator; if the 
information completed is clear and legible. In case of non-conformities related to the ICF these are 
discussed with the PI to be resolved adequately.  
During all these procedures of handling of trial materials, the data collection are designed to 
maintain the volunteer confidentiality within the requirements of Good Clinical Practice, 
Declaration of Helsinki and the trial protocol. 
 
4.2.1.1.5. Source Documents / Case Report Forms (CRF) 
 
Source documents retain all the record data of each volunteer, this document can prove that 
eligibility criteria are applied as defined by the trial protocol. The trial monitoring / auditing is based 
on the information stated in the source documents, and through the source documents it should 
be possible to recreate what happened in a specific situation, so the monitor or auditor can 
reconfirm the data (40). 
The first moment the data is introduced into the source documents is at the screening, after the 
ICF is signed. After that, the document continues to be filled in until the volunteer completes the 
clinical trial and all the adverse events, if any, are all resolved and closed. From this data 
interpretation it will result the final clinical study report (CSR). 
The source documents suffered changes since the first clinical trial in Blueclinical, suffering several 
changes, in order to improve the source documents contents and structure. These changes aimed 
to facilitate the reporting process and the compliance with the protocol requirements and 
specificities. The deviations were detected during monitoring visits and quality reviews. Sometimes 
it can be difficult to transpose the protocol requirements to a document that collects it because of 
the protocol specificities. 
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During the clinical trial, as a CTA I could review the source documents in order to verify if the 
completion was according to the expected, for example, checking if the records were all dated and 
signed, if there are any missing data, etc. In order to protect the volunteer’s rights, safety and well-
being and to guarantee reliable results. Again, as a CTA I must ensure that the information in the 
source documents are accurately reported and are compliant with the GCP’s and the Protocol. 
Collecting data may seem a very simple task, however, ensure that data are accurate and reliable 
can be a complex and detailed task. Along the process, it is always necessary to perform quality 
control, and then the monitors can also perform quality auditing, raising queries as needed. Data 
management performers also launch queries, waiting for our answer of their questions. I had the 
opportunity to enter data from source documents into databases, detect errors or queries raised 
and find the answer to solve them. 
I worked with paper source documents, which were after transcribed to an electronic data 
program. With this transcription I could better confirm and verify the consistency of source 
documents data in paper and the adherence to inclusion/exclusion criteria. I think, if the data 
collection were directly to an electronic system it would make the work of the team easier, reducing 
the amount of work dispensed with this task, reducing the steps of data entry, and probably, also 
could minimize the risk of transcription errors and other errors. To this process work smoothly, the 
electronic solution must be well designed, tested and validated, responding to the needs of the 
investigators and the trial (41, 42). 
 
4.2.1.1.6. Work plans 
 
The work plans are used to guide (physicians and nurses) during the clinical trials according the 
protocol specifications. This task is, essentially, the management of the protocol needs with the 
staff availability while the team is not large, defining the tasks of each member. These documents 
are very important and a small mistake can lead to a big deviation of the protocol, and due to this, 
after the work plans are complete a different person conducts a quality control to assure that the 
plan is well designed. I had the opportunity to perform both of these tasks, create the work plans 
according the protocol needs and also perform quality control when the work plans were created 
by other person. 
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4.2.1.1.7. Stock control and inventory 
 
When I arrived to Phase I Unit, it was still being equipped so I had the opportunity to participate in 
that job. Because of my Nursing background I was preferentially allocated to clinical equipment and 
consumables. During this phase I learned how to contact the suppliers and request budgets, then 
comparing the offers and present the best choices to the Managing Partners to their approval or 
disapproval. Searching for these materials also demanded that I was informed about the product 
characteristics, which improved my knowledge about these materials / equipments. 
Nowadays, the unit is equipped but it is still necessary to check the stock and ordering more 
material and other trial specific products. I have done this task and understand that keep the stock 
up to date it is very important to ensure the quantities needed and to calculate/control the 
expenditures. 
Globally, this task allowed me to better know the equipment and material that the Unit contains, 
and also improve my skills regarding how to deal with suppliers. 
 
 My experience as a Research Nurse 
 
4.2.2.1. Screening, Admission, Confinement and Follow-up 
 
The Research Nurse in the different moments of the clinical trial depends of the CTP guidance. 
Generally, according the CTP, the volunteers must be screened, and this screening procedure 
includes a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG) and 
clinical laboratory tests. The clinical laboratory tests will comprise hematology, biochemistry, 
coagulation, urinalysis, and HIV and hepatitis B and C serology. A urine test to screen for drugs of 
abuse and a breath ethanol test will be performed at screening. In women a serum beta-hCG 
pregnancy test will also be performed. 
In the admission the volunteers are, usually, screened for abuse of alcohol, drugs and pregnancy 
test (in case of women) and also have a new medical history update. In case of any change its clinical 
relevance it is evaluated by the physician and the volunteer can be included or excluded to 
participate in the clinical trial. 
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The confinement is the moment where the volunteer is restrained in the hospital. The last clinical 
trials included periods of confinement because of the blood collection (bioequivalence clinical 
trials). 
It can happen that the clinical trial do not include confinement, it depends of the trial design. 
At the end of study the volunteers repeat vital signs measurement, hematology, plasma 
biochemistry and serum pregnancy test (if woman) tests to verify that they leave the trial as healthy 
as they were when they were included in the trial.  
 
4.2.2.2. Emergency Cart Development and Maintenance 
 
Blueclinical Phase I has appropriate procedures, equipment, medicines and trained staff to deal 
with a medical emergency that might arise during a trial. 
I had the opportunity to collaborate to the Emergency Cart development and now for its daily 
maintenance, according the applicable defined procedures.  
The emergency equipment and rescue medication is organized and maintained according to a SOP 
developed with that purpose. The emergency cart has a defibrillator with an ECG monitor; an 
oxygen cylinder; oropharyngeal airways and face masks; Ambu bag; laryngoscope and endotracheal 
tubes; consumables such as intravenous cannula and fluid infusion sets; emergency medicines, 
including intravenous fluids and others.  
All these components are verified monthly, in order to verify the adequate conditions and expire 
dates. The emergency cart is sealed with a lifeline that is verified every working days or every day 
in case of presence of volunteers in the unit. 
At the same time Phase I Unit is on a hospital site and have a written agreement for 24-hour access 
to the hospital's resuscitation team, to arrive in the unit within a few minutes of an emergency. The 
resus team can be called calling “222”. Blueclinical clinical team is trained in basic, immediate or 
advanced life support procedures, respectively, BLS, ILS, ALS as appropriate. 
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 Other Tasks 
 
4.2.3.1. Laboratory 
 
During this time at Blueclinical I also had the opportunity to participate and learn about the 
laboratory procedures, such as, the activities pre-trial as labelling and quality control, during the 
trial as pipetting and storing the samples and after trial completion as sample shipment. Laboratory 
procedures require a maintenance control of the equipment used, for example the pipettes and 
the centrifuge which also require a periodic calibration to ensure the correct functioning and 
guarantee a reliable result. 
 
4.2.3.1.1. Labels and Quality Control 
 
The labels contents are previously defined by the protocol or the sponsor, if not, according 
Blueclinical internal procedure. The label must contain a minimum set of information, such as, 
protocol no., subject number, study period, sample number, sample series, matrix type. After the 
labels printing, the entirety of labels are copied and archived in TMF. After the copies are ready, a 
different person of who did print and copied the labels perform labels’ quality control. The quality 
control aims to verify if the label information is complete and accurate. 
In different occasions, I performed both of these tasks according the requirements of Blueclinical 
procedures, it requires careful attention to avoid errors later in the trial. 
 
4.2.3.1.2. Sample Management 
 
The sample management includes: Supply, preparation, labeling, handling, shipment and storage. 
All these steps are planned by the laboratory technician in advance and according to protocol or 
instructions of the bioanalytical laboratory. I had a little or no experience in the laboratory 
practices, but I understood the high importance of the sample management since the samples are 
collected till the shipment procedure. The appropriate storage conditions (according to the 
protocol instructions) must be ensured, and the refrigerators/freezers are continuously monitored 
by a temperature logger that alerts in case of deviation of the pre specified temperature range. The 
storage room has access to control restricted to authorized staff. And finally, the last contact with 
the samples is the shipment procedure, at this moment, the samples are packaged according to the 
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bioanalytical laboratory instructions and according to International Air Transportation Association 
(IATA) Dangerous Goods Regulations. I performed an eLearning IATA training learning about the 
required packaging and documentation practices regarding biological samples and dry ice to better 
understand this process. 
During the all process, there are specific forms to fill, such as the records of sample processing at 
the very moment when it happens thereby generating accurate data. These records are archived in 
the TMF. 
 
4.2.3.1.3. Maintenance and Calibration of Laboratory and Clinical Equipment 
 
According the Good Clinical Laboratory Practice (GCLP): “Equipment used should be periodically 
inspected, cleaned, maintained, and calibrated, as appropriate. Records of such maintenance and 
any unscheduled maintenance or calibration should be retained.”(43). 
The laboratory equipment has a maintenance plan according to each equipment specifications. For 
example, the refrigerators and freezers suffer a periodic verification detailed in the operations 
manual. The refrigerators and freezers have also an uninterrupted power supply and emit an 
audible alarm or a visual sign in case of malfunctioning. Due to this, these equipment’s are also 
connect in a centralized way to the hospital alarms (43). 
It was a learning point because I could understand the need of tracking the conditions in how the 
equipment’s are working in order to both assure the quality of the clinical trial results and also to 
ensure the safety of the volunteers who are screened and evaluated with this clinical equipment’s. 
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4.2.3.2. Experience report after an inspection  
 
Phase I Unit had a regulatory inspection conducted by INFARMED, which was another learning 
moment.  
Generally, inspections aims to verify (44, 45): 
 The integrity of the data submitted; 
 Presence of adequate infrastructures; 
 Measures implemented to protect subject’s interest and safety; 
 Quality management system; 
 Compliance with the principles of ICH-GCP and applicable legislation. 
This action helped me to understand the functioning of an inspection and the preparation for its 
implementation. It was a valuable learning, because I find myself faced with the inspection for the 
first time. At the end of the inspection, the findings are discussed and a final report inspection is 
sent, and the inspected site must implement effective Corrective and Preventive Action Plan (CAPA) 
to solve the problems found.  
I must mention that the contact with the competent authorities was very useful, regarding their 
valuable presence and their inputs. Their organization in this area allow them to control what is 
done in clinical research. INFARMED is an orientation point, and regarding their experience they 
can evaluate what is been done and present suggestions for improvement actions to implement. 
And, despite being a very demanding action and very time-consuming, it is essential to standardize 
practices, regulate procedures, ensuring heights of success and the value creation in the context of 
clinical research. 
 
4.2.3.3. Clinical Study Report – eCTD Module 5 
 
Clinical Study Report (CSR) summarizes the results of each clinical trial involving an investigational 
product. Its organization aims to contain clinical data and statistical descriptions, presentations, 
and analyses (46).  
I had the opportunity to contribute to the preparation of a CSR, more specifically Module 5, I could 
help with the document management, preparing documents in pdf format for use in eCTD 
(Common Technical Document) submissions. 
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This participation allowed me to better understand the requested document granularity which 
translates the organization of the CTD. The CSR includes a large quantity of documents, therefore 
a good document management is a very important key to a successful submission.  
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 Discussion 
 
It was with great concern that I grabbed this challenge but at the same time I found it an interesting 
project immediately. Despite knowing in theory, a little of Phase I trials, in practice, until September 
last year, I had no experience in the area.  
I was appointed as a Clinical Trial Assistant Trainee, and when I was asked to take over this function, 
I was immediately aware of the importance of this undertaking, however, I felt a little afraid. 
Blueclinical provided diverse trainings who helped me to improve complementary skills that were 
useful to perform this function in the Phase I Unit, and I have done some autodidactic work to learn 
of some aspects that were important to my work, such as, reading national legislation and 
applicable international guidelines. 
I could understand that even if the clinical trial is internationally funded, with an international 
sponsor, the conduction of the clinical trials implies the involvement of the country directly involved 
in research, mainly through its competent authorities. I could understand the importance of 
transparent and efficient communication with the authorities, because this collaboration ensures 
that the conduction of the clinical trial gathers the requirements in respect of scientific, regulatory 
and ethical aspects. 
This training led me to dwell on the BA/BE trials to understand the principles, methodologies, skills 
and attitudes necessary to implement in order to improve the quality of services and meet the 
challenges that appears to clinical research. This allowed me to understand the importance of the 
role of the CTA, the need to know how to play a role of coordinating logistics and working 
collaboratively with the team and Blueclinical management board. 
There were situations that caused me more constraint due to unexpected changes of timelines. 
Those situations induced an increase on my stress level because in a split second all the priorities 
changed and it demands a great capacity of adaptation to new challenges. It was difficult to cope 
with these changes, especially since I am a novice. One of the strategies I found very important and 
useful to deal with this, was always to have a “Plan B” and never dismiss the associate risks to each 
timeline once they can change without previous notice. These were also learning points, since it is 
very likely that similar situations will happen in the future and at that time I'll be more prepared.  
I became aware of the challenges facing clinical research in the current context and the emerging 
opportunities. It is my belief that the challenges are more difficult to operationalize, but vital to the 
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present time. I realized the rigor required in clinical research and the need for justification of our 
practice by collecting evidence. Furthermore, the learning process has been crucial to define 
improvement actions and how to implement them. 
As I, Blueclinical Phase I Unit was taking its first steps, so, it was even more challenging, because I 
could participate in an early stage of the Unit development activities, such as, SOPs writing, material 
acquisitions and other activities. This allowed me to learn some hurdles in project management, 
such as budget and timelines definition and fulfillment. Taking these “baby-steps” was crucial to 
my learning outcomes during this training period. Now, both I and the Unit benefit from all the 
evolution and growth. As I proposed in the beginning of this training, these tasks helped me to 
achieve the goal: “be proactive and help to brainstorm new ideas” to improve the functional 
network of the Unit. 
The final balance is very positive. I believe that most of the objectives were met and I am now much 
more able to apply this knowledge in future tasks. Nevertheless, I think I still have to continue to 
improve my skills in project management, as I want to perform these tasks in the future, working 
closely with investigators, project managers and other study team members to ensure optimal 
coordination of clinical research activities. 
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 Conclusion 
 
During this period of time I actively participated in several clinical trials. I noticed a significant 
personal evolution and professional development in this area and I could also verify that a practice-
based experience allows an effective learning. 
BA/BE clinical trials are complex and a highly competitive market and to survive and to be successful 
it is required an extensive knowledge about the process, regulations and project management. 
Furthermore, experience is also required, so I am very glad for have had this opportunity at 
Blueclinical, because this training contributed for both: first, to increase my knowledge and second, 
to acquire some experience.  
One of the aspects I noticed an improvement on was my organizational and time management 
skills. During the first months I felt the need to improve this aspect in order to better organize my 
time and, ten months later I can say I accomplished it, by acquiring simple but sacred strategies, 
such as, writing task lists and defining priorities. Furthermore, now I can better assess some of the 
major difficulties that can arise during the preparation and development of Phase I clinical trials 
and I developed strategies to deal with it. Some difficulties were, for example, time stress, 
reworking the procedures and training the clinical team to be compliant with the protocol and SOPs. 
The strategies included better organization and a supportive teamwork environment. 
I had also learned that communication is an essential tool for this job, in many respects, including 
communication with competent authorities, clients, volunteers, and even within the team. I was 
able to improve it by performing some activities during my internship, for example, by recruiting 
volunteers. Although I learned a lot already, in the future, I still would like to better develop my 
communication skills, to efficiently communicate with sponsors and study teams. 
As I mentioned before, organization, time and resources management are essential to the success 
of any project, as well as teamwork and motivation and these were my pillars. My goals to the 
future include to growing within the clinical research, improve my leadership, possibly, by attending 
a leadership course, interpersonal and technical skills and assume additional responsibilities. And, 
last but not least, continue to learn and increase my value to high quality clinical research.  
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Appendix A – Blueclinical Organogram and List of Acronyms 
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